There have been no clinically pertinent changes compared to 2011 aside from new knowledge and new recommendations with regards to the cure with bisphosphonates and denosumab (see area ‘Bisphosphonates and RANKL Antibody Denosumab’). Within the INSEMA examine – a prospectively randomized review evaluating SLNE vs. no SLNE in patients https://carlosj208bkr4.wikiconversation.com/user